$5.57
5.03%
Nasdaq, Nov 20, 03:59 pm EST. Closed.
ISIN
US67576A1007
Symbol
OCUL

Ocular Therapeutix Inc Stock price

$5.57
-1.08 16.24% 1M
-2.46 30.64% 6M
-6.57 54.12% YTD
-6.15 52.47% 1Y
+3.22 137.02% 3Y
-0.95 14.57% 5Y
-4.60 45.23% 10Y
-7.58 57.64% 20Y
Nasdaq, Closing price Fri, Nov 20 2026
-0.29 4.95%
ISIN
US67576A1007
Symbol
OCUL
Industry

AI Insights on Ocular Therapeutix Inc Insights AI Insights on Ocular Therapeutix Inc

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is Ocular Therapeutix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,086 stocks worldwide.

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$699.7m
Net debt
positive
Cash
$598.6m
Shares outstanding
219.6m
Valuation
P/E
negative
P/S | estimate
23.5 | 23.5
EV/Sales | estimate
13.4 | 13.4
EV/FCF | ex SBC
negative | negative
P/B
2.4
Financial Health
Equity Ratio
81.0%
Return on Equity
-40.6%
ROCE
-50.5%
ROIC
-
Debt/Equity
0.1
Share-Based Compensation & Dilution
SBC | % of Revenue
$53.3m | 102.4%
SBC as % of FCF
-
SBC Growth 1Y
56.8%
Share Count Growth 1Y
27.0%
Shareholder Yield
-27.0%
Financials
Revenue | estimate
$52.1m | $52.1m
EBITDA
$-308.5m
EBIT
$-313.9m
Net Income
$-301.5m
Free Cash Flow | ex SBC
$-255.1m | $-308.4m
Growth
Revenue | estimate
-8.1% | 0.3%
EBITDA
-37.6%
EBIT
-37.6%
Net Income
-39.1%
Free Cash Flow
-42.2%
Margin
Gross
87.1%
EBITDA
-592.6%
EBIT
-603.0%
Net
-579.1%
Free Cash Flow | ex SBC
-490.1% | -592.4%
More
EPS
$-1.3
FCF per Share
$-1.2
Short interest
15.6%
Employees
325
Rev per Employee
$160.0k

Ocular Therapeutix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Ocular Therapeutix Inc forecast:

18x Buy
95%
1x Hold
5%

Analyst Opinions

19 Analysts have issued a Ocular Therapeutix Inc forecast:

Buy
95%
Hold
5%

Ocular Therapeutix Inc Events

Past Events
NOV
17
UBS Global Biopharma Conference 2026
4 days ago
NOV
9
Q3 2026 Earnings Call
12 days ago
OCT
22
Special Call - Ocular Therapeutix, Inc.
30 days ago
AUG
17
Special Call - Ocular Therapeutix, Inc.
3 months ago
JUN
17
Analyst/Investor Day - Ocular Therapeutix, Inc.
5 months ago
MAY
12
Bank of America Global Healthcare Conference 2026
6 months ago
MAY
5
Q1 2026 Earnings Call
7 months ago
MAR
2
Special Call - Ocular Therapeutix, Inc.
9 months ago
FEB
17
Special Call - Ocular Therapeutix, Inc.
9 months ago
NOV
4
Q3 2025 Earnings Call
about one year ago

Financial data from Ocular Therapeutix Inc

Jun '26
+/-
%
52 52
8% 8%
100%
- Direct Costs 6.71 6.71
12% 12%
13%
45 45
10% 10%
87%
- Selling and Administrative Expenses 136 136
27% 27%
261%
- Research and Development Expense 224 224
30% 30%
429%
-308 -308
38% 38%
-593%
- Depreciation and Amortization 5.45 5.45
39% 39%
10%
EBIT (Operating Income) EBIT -314 -314
38% 38%
-603%
Net Profit -301 -301
39% 39%
-579%

In millions USD.

Don't miss a Thing! We will send you all news about Ocular Therapeutix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocular Therapeutix Inc Stock News

Neutral
GlobeNewsWire
●
about 19 hours ago
BEDFORD, Mass., Nov. 20, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement awards to Ms. Tiffany Howard, the Company's new Executive Vice President, Commercial – Retina. The awards were made as an inducement material to ...
Neutral
GlobeNewsWire
●
12 days ago
AXPAXLI™ NDA submission for wet AMD on track for 4Q 2026 following upcoming SOL-R interim Week 52 safety analysis Several FDA interactions, including most recent September 2026 Pre-NDA Meeting, reaffirm alignment on submission package under 505(b)(2) pathway SOL-1 post-hoc analyses presented at AAO and Empire Forum show subjects without early persistent retinal fluid and fluid variability had b...
More Ocular Therapeutix Inc News

Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Head office United States
CEO Dr. Dugel
Employees 325
Founded 2006
Website www.ocutx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today